Amolyt Pharma has received Fast Track designation from the FDA for its Phase 3 development targeting hypoparathyroidism. The Fast Track process expedites drug review for serious conditions with unmet medical needs.

Amolyt Pharma, emphasized the significance of this designation in addressing the unmet needs of hypoparathyroidism patients. He pledged to maintain a productive dialogue with the FDA to advance treatment options for this rare disease.

Dr. Mark Sumeray highlighted the limitations of current treatments for hypoparathyroidism and the potential of eneboparatide based on promising Phase 2 results. The ongoing Phase 3 Calypso study aims to validate these findings, with results expected in 2025.

The Calypso study is a randomized, placebo-controlled trial assessing eneboparatide's efficacy and safety in chronic hypoparathyroidism patients. It includes endpoints such as serum calcium normalization and improvements in urinary excretion, symptoms, and quality of life. The study involves over 50 centers across the US, Europe, Canada, and the UK.

Fast Track designation offers benefits such as enhanced FDA engagement and potential expedited approval pathways. Hypoparathyroidism, characterized by low PTH levels and related complications, affects a significant number of individuals globally, particularly postmenopausal women who are at risk of osteoporosis and kidney-related issues.

Eneboparatide, an investigational peptide, targets PTH receptors to regulate calcium metabolism and reduce urinary calcium excretion. Its unique mechanism and short half-life may offer advantages in preserving bone integrity, crucial for peri- and postmenopausal women prone to osteoporosis.

Amolyt Pharma's commitment to addressing the clinical needs of hypoparathyroidism patients underscores the importance of advancing therapeutic options for rare endocrine diseases.

 

Source: globenewswire.com

Report Abuse